Effects of adjunctive verapamil administration in chronic schizophrenic patients.
1. The efficacy of adjunctive verapamil on psychopathological symptoms and tardive dyskinesia was investigated in 22 chronic schizophrenic patients, who had partially responded to neuroleptics. 2. After 28 days verapamil administration (240 mg/day) a significant improvement was found in anxiety-depression, and in some positive and negative symptoms. Three of the 22 patients showed clinically pronounced global improvement. 3. The treatment was ineffective in tardive dyskinesia.
Bartko
G
G
National Institute for Nervous and Mental Diseases, Budapest, Hungary.
Horvath
S
S
Zador
G
G
Frecska
E
E
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D014700:Verapamil / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D014700:Verapamil